31 January 2012 - US biotech Medistem Inc (PINK:MEDS) and its Russian licensee ERCell LLC said they had initiated Phase II RECOVER-ERC trial dosing three patients with heart failure with Medistem's Endometrial Regenerative Cell (ERC) stem cell product.

The study will evaluate safety an...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up